Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia

BACKGROUND Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia. Given these mixed results we examined whether galantamine compared to adjunctive placebo may improve cognitive functions in patients treated concomitantly with a long acting atypical antipsychotic. METHOD The parent study was a 52-week double-blind, randomized study of treatment with long-acting injectable risperidone 25mg or 50mg every two weeks. Adjunctive galantamine or placebo treatment was administered from Month 6 to 12. Outcome measures were neurocognitive, psychopathology, social and quality of life functions. Patients were randomized to blinded galantamine up to 24mg/day or matching placebo tablets. All patients were maintained on their randomized long-acting injectable risperidone regimen for the duration of the trial. RESULTS 32 patients were included in the intent-to-treat analysis. No statistically significant differences were found for Attention Vigilance, Declarative Memory, Processing Speed, Reasoning/Problem Solving, Working Memory domains and the Neurocognitive Composite Score. Group specific analysis showed a statistically significant group interaction (p=0.043) with the Social Cognition domain showing in the galantamine group significantly lower scores at endpoint than placebo patients. The PANSS general psychopathology subscale showed significantly higher scores in the galantamine group at endpoint (p=0.05). ANCOVA model for within treatment group comparisons showed a significant increase of 7.3 points for the total PANSS score for the galantamine group. CONCLUSION Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used.

[1]  G. Simpson,et al.  A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. , 2006, The Journal of clinical psychiatry.

[2]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[3]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[4]  J. A. Dani,et al.  Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release , 2004, Molecular Pharmacology.

[5]  J. Stevens.  Applied Multivariate Statistics for the Social Sciences , 1986 .

[6]  D. Mash,et al.  Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. , 1995, Life sciences.

[7]  E. Tangalos,et al.  Understanding the Diagnostic Capabilities of Cognitive Tests , 2001, The Clinical neuropsychologist.

[8]  K. Davis,et al.  Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits , 1995, Journal of neurochemistry.

[9]  W. M'Ilwaine.  The Religious Aspect of Ulster Revivalism , 1860 .

[10]  A. Graybiel,et al.  Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia , 1999, Neuroscience.

[11]  J. Lindenmayer,et al.  Five‐Factor Model of Schizophrenia Initial Validation , 1994, The Journal of nervous and mental disease.

[12]  R. Buchanan,et al.  Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. , 2002, The American journal of psychiatry.

[13]  Young Hoon Kim,et al.  A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia , 2007, International clinical psychopharmacology.

[14]  R. Potthoff,et al.  A generalized multivariate analysis of variance model useful especially for growth curve problems , 1964 .

[15]  L. Opler,et al.  The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation , 1989, British Journal of Psychiatry.

[16]  T. Robbins,et al.  The Effects of AMPA‐induced Lesions of the Septo‐hippocampal Cholinergic Projection on Aversive Conditioning to Explicit and Contextual Cues and Spatial Learning in the Water Maze , 1995, The European journal of neuroscience.

[17]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[18]  Keith A. Young,et al.  Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone , 2006, Biological Psychiatry.

[19]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[20]  Martin Radina,et al.  Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  Michael A. Dyer,et al.  High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia , 2008, Schizophrenia Research.

[22]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[23]  Robert Rosenthal,et al.  Computing Contrasts, Effect Sizes, and Counternulls on Other People's Published Data: General Procedures for Research Consumers , 1996 .

[24]  H. Geerts,et al.  Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits , 2005, Brain Research.

[25]  D. Braff,et al.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? , 2000, Schizophrenia bulletin.

[26]  Maryam Noroozian,et al.  A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  J. McEvoy,et al.  Galantamine for treatment-resistant schizophrenia. , 2002, The American journal of psychiatry.

[28]  E X Albuquerque,et al.  Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. , 1996, Molecular pharmacology.

[29]  B. Dean,et al.  Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. , 2001, The American journal of psychiatry.